Fahimeh Abdollahimajd; Reem Diab; Hamideh Moravvej; Ayda Bahmanjahromi; Sahar Dadkhahfar; Azadeh Goodarzi; Afsaneh Sadeghzadeh Bazargan; Sayyed Mojtaba Nekooghadam; Mohammad Nikvar; Mohammad Shahidi Dadras
Abstract
Background: Cutaneous manifestations of coronavirus disease 2019 (COVID-19) are not uncommon and can be the presenting sign of the disease. We aimed to investigate the cutaneous manifestations in COVID-19 patients.Methods: This cross-sectional study was performed on COVID-19 patients referred to Shohada-e ...
Read More
Background: Cutaneous manifestations of coronavirus disease 2019 (COVID-19) are not uncommon and can be the presenting sign of the disease. We aimed to investigate the cutaneous manifestations in COVID-19 patients.Methods: This cross-sectional study was performed on COVID-19 patients referred to Shohada-e Tajrish and Modarres hospitals, Tehran, Iran, from January 1, 2021 to March 31, 2021. Patients with cutaneous lesions were included in the study; if needed, patients were visited in person, and a biopsy was taken.Results: Of the 100 COVID-19 patients in this study, with a mean age of 45.53 ± 17.75 years, 37 (37%) were males. The most common cutaneous manifestation was urticaria (21%), followed by maculopapular eruptions (17%), petechiae/purpura (15%), pityriasis rosea-like lesions (15%), erythema multiforme (7%), pernio (6%), Vesicles/pseudovesicles/bullae (5%), and others (24%). Most lesions were erythematosus (87.63%). Legs (40%) were most frequently involved. The most common accompanying symptom was pruritus (52%), followed by burning sensations (18%) and pain (7%). Six patients had mucosal lesions; these lesions were the only mucocutaneous manifestations in three of them. Skin biopsies were taken from 11 patients, revealing epidermal changesin 10 (90.9%), dermal changes in 7 (63.6%), mucin deposition in 1 (9.1%), perivascular lymphocyte infiltration in 10 (90.9%), and neutrophil infiltration in 1 (9.1%).Conclusion: The frequency of skin manifestations was relatively high in this study, with urticaria as the most common cutaneous presentation of COVID-19. Special attention must be paid to the cutaneous lesions of COVID-19.
Mohammad Shahidi-Dadras; Farnaz Araghi; Fahimeh Abdollahimajd; Mehdi Gheisari; Ali Forghanian; Sahar Dadkhahfar
Abstract
During the current coronavirus disease 2019 (COVID-19) pandemic, patients with malignancies like primary cutaneouslymphomas (PCLs) are considered at high risk for severe disease progression given their underlying condition. Mycosis fungoides (MF) is a type of PCL that often needs lifelong treatments, ...
Read More
During the current coronavirus disease 2019 (COVID-19) pandemic, patients with malignancies like primary cutaneouslymphomas (PCLs) are considered at high risk for severe disease progression given their underlying condition. Mycosis fungoides (MF) is a type of PCL that often needs lifelong treatments, including immunosuppressive drugs that predispose patients to catastrophic COVID-19 outcomes. Accordingly, several issues are to be addressed in the management of patients with MF. First of all, patients with this chronic condition may lose access to healthcare services such as phototherapy and inpatient treatments like electron beam therapy. Secondly, the patients’ anxiety of becoming infected while referring for the follow-up visits might impair their adherence to treatments. Finally, the current situation may affect the management strategies of dermatologists adopted for MF patients.We decided to perform this teledermatology study to assess the clinical condition of patients with MF in our referral center. We also evaluated patients’ perceived anxiety during the COVID-19 pandemic based on the Corona Disease Anxiety Scale (CDAS). Our results demonstrated that lockdown could influence adherence to treatment modalities (especially phototherapy) in these patients.
Mohammad Shahidi Dadras; Sahar Dadkhahfar; Ayda Bahmanjahromi; Hannane Seifian; Fahimeh Abdollahimajd
Abstract
The coronavirus disease 2019 (COVID-19) has emerged as a worldwide pandemic. In addition to pulmonary symptoms, reports of the involvement of other organs such as the skin are being published. We present the cases of three COVID-19 patients who presented with cutaneous manifestations ...
Read More
The coronavirus disease 2019 (COVID-19) has emerged as a worldwide pandemic. In addition to pulmonary symptoms, reports of the involvement of other organs such as the skin are being published. We present the cases of three COVID-19 patients who presented with cutaneous manifestations and review the previous reports. Purpura and petechiae, erythematous papules andmacules, and urticarial eruptions are signs seen in the presented cases. Although a growing number of cutaneous manifestations of COVID-19 have been reported, there is no doubt that further reports of both typical and atypical presentations are needed to confirm and understand skin involvement in COVID-19. Since COVID-19 manifests in various forms, dermatologists, as thefirst line of dealing with patients who come with skin rashes, should always be aware of the early diagnosis of this disease.
Leila Nabai; Mohammad Ebrahimzadeh Ardakani; Mohammad Shahidi Dadras; Soheila Nasiri
Volume 10, Issue 1 , 2007, , Pages 32-36
Abstract
Background and aim: Diabetes mellitus is a metabolic disease with multiple complications. Skin tag is a pedunculated papule, which is more common in women and has been suggested as a cutaneous marker of diabetes mellitus. The aim of this study was to determine the frequency of diabetes mellitus in patients ...
Read More
Background and aim: Diabetes mellitus is a metabolic disease with multiple complications. Skin tag is a pedunculated papule, which is more common in women and has been suggested as a cutaneous marker of diabetes mellitus. The aim of this study was to determine the frequency of diabetes mellitus in patients with skin tags.Materials and methods: This descriptive study was done on 100 patients with skin tags. The investigation included fasting blood sugar (FBS) and glucose tolerance test (GTT).Results: 66 patients had normal FBS, 27 had diabetes mellitus, 5 had impaired GTT and 2 had impaired fasting glucose. Over all, 34 had abnormal glucose metabolism, 7 were unaware of their metabolic abnormality. Among 40 hospitalized patients 50% had abnormal glucose metabolism meanwhile 23.3% of 60 outpatients had this abnormality (p<0.01). No association was seen between BMI, obesity, gender, location and number of skin tags with abnormal metabolism of glucose.Conclusion: It is recommended to consider skin tags as a cutaceous marker for abnormality of glucose metabolism.